| Literature DB >> 27160966 |
María Gómez-Serrano1, Emilio Camafeita2, Eva García-Santos1, Juan A López2, Miguel A Rubio3, Andrés Sánchez-Pernaute4, Antonio Torres4, Jesús Vázquez2, Belén Peral1,5.
Abstract
Obesity is a main global health issue and an outstanding cause of morbidity and mortality predisposing to type 2 diabetes (T2DM) and cardiovascular diseases. Huge research efforts focused on gene expression, cellular signalling and metabolism in obesity have improved our understanding of these disorders; nevertheless, to bridge the gap between the regulation of gene expression and changes in signalling/metabolism, protein levels must be assessed. We have extensively analysed visceral adipose tissue from age-, T2DM- and gender-matched obese patients using high-throughput proteomics and systems biology methods to identify new biomarkers for the onset of T2DM in obesity, as well as to gain insight into the influence of aging and gender in these disorders. About 250 proteins showed significant abundance differences in the age, T2DM and gender comparisons. In diabetic patients, remarkable gender-specific hallmarks were discovered regarding redox status, immune response and adipose tissue accumulation. Both aging and T2DM processes were associated with mitochondrial remodelling, albeit through well-differentiated proteome changes. Systems biology analysis highlighted mitochondrial proteins that could play a key role in the age-dependent pathophysiology of T2DM. Our findings could serve as a framework for future research in Translational Medicine directed at improving the quality of life of obese patients.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27160966 PMCID: PMC4861930 DOI: 10.1038/srep25756
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1VAT samples and comparative proteomic studies.
Two main groups of patients were considered: patients with T2DM (diabetic obese) and patients without T2DM (non-diabetic obese). Four groups (n = 4 each) were constituted as follows: non-diabetic obese women over 45 years, non-diabetic obese women under 35 years, diabetic obese women over 45 years and diabetic obese men over 45 years. Proteins were extracted from individual VAT samples, pooled in their corresponding group and digested. The peptide pools were tagged with iTRAQ labels (indicated with different colours) and mixed. The multiplexing capacity of iTRAQ technology allowed three differential expression studies.
Figure 2Protein abundance changes in VAT from obese patients.
(A) Dot-plots of protein mean-corrected log2 ratios, X′q, vs. their corresponding statistical weight, Wq, showing normal distribution of data in each statistical comparison: age (1), T2DM (2) and gender (3). (B) Area-proportional Venn’s diagram showing the number of DAPs in the three statistical comparisons obtained with BioVenn software72. (C) Relative overlapping of DAPs among comparisons. (D) Number of total, up- and down-regulated DAPs specific to each comparison. For further information regarding protein changes and statistical values see also Supplementary Table S3.
Representative enriched categories with some of their DAP components.
| UniProt | Protein name | Symbol | Zq | ||
|---|---|---|---|---|---|
| Age comparison | |||||
| 0.00 | P14780 | Matrix metalloproteinase-9 | MMP9 | 4.25 | |
| Q12805 | EGF-containing fibulin-like extracellular matrix protein 1 | EFEMP1 | 3.54 | ||
| P55268 | Laminin subunit beta-2 | LAMB2 | 2.90 | ||
| P51888 | Prolargin | PRELP | 2.64 | ||
| P02462 | Collagen alpha-1(IV) chain | COL4A1 | 2.45 | ||
| P12110 | Collagen alpha-2(VI) chain | COL6A2 | 2.37 | ||
| 0.00 | P16401 | Histone H1.5 | HIST1H1B | −2.16 | |
| P62805 | Histone H4 | HIST1H4A | −2.69 | ||
| Q02539 | Histone H1.1 | HIST1H1A | −3.04 | ||
| 0.04 | Q8NC60 | Nitric oxide-associated protein 1 | NOA1 | −2.20 | |
| P06241 | Tyrosine-protein kinase Fyn | FYN | −2.21 | ||
| P24310 | Cytochrome c oxidase subunit 7A1, mitochondrial | COX7A1 | −2.22 | ||
| Q9NS69 | Mitochondrial import receptor subunit TOM22 homolog | TOMM22 | −2.27 | ||
| P51970 | NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 8 | NDUFA8 | −2.28 | ||
| P53007 | Tricarboxylate transport protein, mitochondrial | SLC25A1 | −2.42 | ||
| T2DM comparison | |||||
| 0.00 | P06702 | Protein S100-A9 | S100A9 | 3.61 | |
| P07996 | Thrombospondin-1 | THBS1 | 3.25 | ||
| P05109 | Protein S100-A8 | S100A8 | 3.05 | ||
| P55083 | Microfibril-associated glycoprotein 4 | MFAP4 | 2.81 | ||
| P13796 | Plastin-2 | LCP1 | 2.06 | ||
| P06703 | Protein S100-A6 | S100A6 | 2.02 | ||
| 0.00 | P99999 | Cytochrome c | CYCS | −2.01 | |
| O75964 | ATP synthase subunit g, mitochondrial | ATP5L | −2.02 | ||
| P50213 | Isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial | IDH3A | −2.04 | ||
| O75947 | ATP synthase subunit d, mitochondrial | ATP5H | −2.11 | ||
| Q5VTU8 | ATP synthase subunit epsilon-like protein, mitochondrial | ATP5EP2 | −2.12 | ||
| O75390 | Citrate synthase, mitochondrial | CS | −2.27 | ||
| Q02252 | Methylmalonate-semialdehyde dehydrogenase [acylating], mitochondrial | ALDH6A1 | −2.27 | ||
| P05091 | Aldehyde dehydrogenase, mitochondrial | ALDH2 | −2.29 | ||
| Q5VT66 | Mitochondrial amidoxime-reducing component 1 | MARC1 | −2.43 | ||
| P38117 | Electron transfer flavoprotein subunit beta | ETFB | −2.44 | ||
| Gender comparison | |||||
| 0.00 | P02763 | Alpha-1-acid glycoprotein 1 | ORM1 | 5.44 | |
| P04003 | C4b-binding protein alpha chain | C4BPA | 3.67 | ||
| P05155 | Plasma protease C1 inhibitor | SERPING1 | 3.15 | ||
| P10909 | Clusterin | CLU | 2.73 | ||
| P02751 | Fibronectin | FN1 | 2.42 | ||
| 0.01 | P49327 | Fatty acid synthase | FASN | 5.59 | |
| Q53TN4 | Cytochrome b reductase 1 | CYBRD1 | 4.35 | ||
| P00450 | Ceruloplasmin | CP | 4.21 | ||
| P07203 | Glutathione peroxidase 1 | GPX1 | 2.94 | ||
| O75891 | Cytosolic 10-formyltetrahydrofolate dehydrogenase | ALDH1L1 | 2.69 | ||
| P22352 | Glutathione peroxidase 3 | GPX3 | 2.03 | ||
| 0.00 | P40939 | Trifunctional enzyme subunit alpha, mitochondrial | HADHA | −2.03 | |
| Q13162 | Peroxiredoxin-4 | PRDX4 | −2.73 | ||
| P00441 | Superoxide dismutase [Cu-Zn] | SOD1 | −2.81 | ||
| P00352 | Retinal dehydrogenase 1 | ALDH1A1 | −3.08 | ||
| P07195 | L-lactate dehydrogenase B chain | LDHB | −3.09 | ||
| P21397 | Amine oxidase [flavin-containing] A | MAOA | −3.16 | ||
| P08294 | Extracellular superoxide dismutase [Cu-Zn] | SOD3 | −3.74 | ||
| Q92781 | 11-cis retinol dehydrogenase | RDH5 | −6.65 | ||
| 0.00 | P09211 | Glutathione S-transferase P | GSTP1 | −2.35 | |
| P28161 | Glutathione S-transferase Mu 2 | GSTM2 | −2.55 | ||
| P30711 | Glutathione S-transferase theta-1 | GSTT1 | −3.49 | ||
| P09488 | Glutathione S-transferase Mu 1 | GSTM1 | −5.63 | ||
Functional categories were retrieved from the DAVID database. The p value for each term is shown. Relative abundance change of proteins is indicated with the corresponding Zq value for each comparison. These values can also be found in the extended Supplementary Table S3, where a colour scale in red and blue colours is represented for up- and down-regulated proteins, respectively.
Figure 3Western blot and immunohistochemistry analyses for DAP validation.
(A) IHC detection of TOM22 in VAT samples from 4 older and 4 younger non-diabetic patients showing over-expression of TOM22 staining (in brown) in younger adipose cells, mainly surrounding the nuclei where the mitochondrial are located (arrows). Magnification x200 under Nikon Eclipse 90i microscope. a, adipocyte. Scale bars, 50 μm. (B–D) Representative WB analyses of selected DAPs using an additional set of 32 VAT samples (8 per cohort) in age, T2DM and gender comparisons. The results were normalized for B-actin density. Underneath, the values for relative intensity obtained after densitometry of the bands are means ± SD. Statistical significance was set at p < 0.05.
Figure 4Protein function dynamics in obese patients.
(A–C) Clustering of the functional categories altered in the age (A), T2DM (B) and gender (C) comparisons. A colour scale was used to represent up-regulated categories in red and down-regulated in blue. A detailed version of clustered categories is displayed in Supplementary Tables S7, S8, S9, respectively. (D–F) Alteration of representative cluster categories in the age (D), T2DM (E) and gender (F) comparisons. The cumulative frequency of changes (Zq) for the least redundant category in each of the clusters highlighted is represented together with a theoretical curve showing a normal distribution of data and the experimental curve representing Zq for the whole set of proteins quantified.
Figure 5Evaluation of adipose tissue cellularity based on histological section analyses.
Haematoxylin-eosin stained images from obese diabetic women (n = 4) and obese diabetic men (n = 4) were analysed using Adiposoft software. A total of 72 high-resolution images were randomly acquired for the analyses. Minimal and maximum threshold for automated measurement of adipocyte diameter was set at 40 μm and 175 μm, respectively. (A) Normal distribution of mean-area (μm2) and mean-equivalent diameter (μm) in diabetic women (black series, n = 327) and men (red series, n = 349) adipocytes from a representative experiment. (B) % of total adipocytes according to different mean-equivalent diameter ranges (in μm). Bars represent the average of the relative percent of adipocytes in each range ± SD from each group among three independent experiments. Statistical significance between diabetic women and men was set at p < 0.05. (C) Representative haematoxylin-eosin fields at x40 (left panel) and x100 (right panel) magnification used for adipocyte size estimation in both diabetic women and men. Scale bars, 100 μm.
Figure 6Systems biology approach to the prediction of protein function alterations in T2DM and aging.
(A) Computational modelling according to TPMS technology. The DAPs from the iTRAQ-based proteomic study were analysed through computational modelling of 3 cohorts: non-diabetic obese women under 35 years, non-diabetic obese women over 45 years and diabetic obese women over 45 years. Three mathematical models were generated and each of them was challenged with the stimulus (the most relevant proteins triggering T2DM) and the response (T2DM effectors). The most probable molecular pathways leading from the stimulus to the response through the biological network were traced, revealing the most probable molecular mechanisms to develop T2DM in each of the three cohorts. By comparing the mathematical models, a set of functionally differential proteins was obtained (p value < 0.05). A detailed description of TPMS technology can be found in Supplemental Experimental Procedures. (B,C) Mechanistic predictions related to the onset of T2DM and hypothetical interpretation of data. (B) SRC is more activated in both non-diabetic (T2DM comparison) and younger women (age comparison). (C) SHC1 inhibition was predicted as over-represented in older (age comparison) and diabetic patients (T2DM comparison). Conversely, SHC1 activation was also over-represented in older non-diabetic women (T2DM comparison). We acknowledged Anaxomics Biotech. for panel (A) drawings.